Robotic vs. open partial cytoreductive nephrectomy in metastatic renal cell carcinoma: adverse in-hospital outcomes

机器人辅助与开放式部分细胞减灭性肾切除术治疗转移性肾细胞癌:不良住院结局

阅读:1

Abstract

OBJECTIVE: To test for adverse in-hospital outcomes after robotic (RPCN) vs. open partial cytoreductive nephrectomy (OPCN). METHODS: RPCN and OPCN patients were retrospectively identified within the National Inpatient Sample database (2008-2019). Propensity score matching (PSM, ratio 1:2) and multivariable logistic regression models (LRM) were used. RESULTS: Of 491 patients, 139 (28%) underwent RPCN vs. 352 (72%) OPCN. RPCN-rate increased from 4.2 to 42.5% over time (p < 0.001). RPCN patients exhibited similar age, comorbidity and race/ethnicity distribution relative to their OPCN counterparts. After 1:2 PSM, all 139 RPCN and 278 of 352 (79%) OPCN patients were included. Relative to OPCN, RPCN patients exhibited lower rates in four of 10 examined adverse in-hospital outcomes: intraoperative complications (< 3 vs. 9%, p = 0.02), pulmonary complications (6 vs. 14%, p = 0.02), blood transfusions (< 5 vs. 14%, p = 0.004) and exhibited shorter median length of stay (2 vs. 4 days, p < 0.001). In multivariable LRMs, RPCN independently predicted lower rates in the same four of 10 categories with odds ratio (OR) ranging from 0.17 to 0.34. Largest magnitude was recorded in shorter length of stay (OR 0.17, p < 0.001), followed by intraoperative complications (OR 0.24, p = 0.02), use of blood transfusions (OR 0.25, p = 0.003) and pulmonary complications (OR 0.34, p = 0.01). No differences in in-hospital mortality were recorded. CONCLUSION: Rates of RPCN has increased exponentially over time (4.2 to 42.5%). Relative to OPCN, RPCN is associated with fewer adverse in-hospital outcomes and shorter hospital stay. However, no differences regarding in-hospital mortality were recorded between RPCN and OPCN.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。